Provided by Tiger Trade Technology Pte. Ltd.

Korro Bio, Inc.

12.29
-0.2050-1.64%
Volume:18.31K
Turnover:225.93K
Market Cap:180.90M
PE:-1.24
High:12.64
Open:12.26
Low:12.19
Close:12.49
52wk High:55.89
52wk Low:5.20
Shares:14.73M
Float Shares:10.47M
Volume Ratio:0.57
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.8800
EPS(LYR):-12.4806
ROE:-97.69%
ROA:-27.95%
PB:1.75
PE(LYR):-0.98

Loading ...

Korro Bio posts corporate presentation on RNA-editing genetic medicines pipeline

Reuters
·
May 07

Korro Bio Q1 FY26 net loss narrows to $19.6 million; R&D expenses fall to $12.9 million

Reuters
·
May 07

Korro Bio Inc Qtrly EPS $-1.69

THOMSON REUTERS
·
May 07

Korro Bio Inc - Reports Cash, Cash Equivalents and Marketable Securities of $157.1 Mln as of March 31, 2026

THOMSON REUTERS
·
May 07

Korro Bio Inc - Reports No Collaboration Revenue for Q1 2026

THOMSON REUTERS
·
May 07

Korro Bio Inc - Expects Cash Position to Fund Operations Into Second Half of 2028

THOMSON REUTERS
·
May 07

Korro Bio participates in HCW BioConnect Nasdaq investor conference fireside chat

Reuters
·
May 06

Korro Bio Inc expected to post a loss of $1.84 a share - Earnings Preview

Reuters
·
May 01

Korro Bio to present preclinical KRRO-121 hyperammonemia data at ASGCT meeting

Reuters
·
Apr 16

Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences

THOMSON REUTERS
·
Apr 16

Korro Bio announces annual shareholder meeting notice

Reuters
·
Apr 16

BRIEF-Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 11

Korro Bio grants new-hire inducement option for 15,000 shares at $13.46 each

Reuters
·
Apr 11

Korro Bio initial beneficial ownership filing shows Lynx1 Capital Management as 10% owner

Reuters
·
Apr 03

Korro Bio Inc. publishes corporate presentation on RNA editing genetic medicines and pipeline milestones

Reuters
·
Mar 20

Korro Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 16

Korro Bio files to sell 7.65M shares of common stock for holders

TIPRANKS
·
Mar 14

Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Benzinga Earnings
·
Mar 14

Korro Bio Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Mar 13

Korro Bio price target raised to $22 from $21 at Cantor Fitzgerald

TIPRANKS
·
Mar 13